Skyhawk eligible to receive up to 1.8 bln usd from deal (Il Sole 24 Ore Radiocor) - Paris, 22 Apr - French biopharmaceutical company Ipsen said it has signed an exclusive worldwide collaboration with Skyhawk Therapeutics to discover and develop novel small molecules that modulate RNA for rare neurological diseases.

The agreement includes an option pursuant to which Ipsen would acquire exclusive license for the worldwide rights to develop successful development candidates (DC). Following successful DC nomination, Ipsen will be responsible for all activities. Skyhawk's unique platform accelerates building RNA-targeting small molecules across several therapeutic areas, including rare neurological diseases.

Under the terms of the agreement Skyhawk is eligible to receive up to 1.8 billion dollars in development, regulatory and commercial milestones, including an upfront payment, for the option and research collaboration, plus potential for tiered royalties.

AAA-Sch

(RADIOCOR) 22-04-24 08:00:30 (0062) 5 NNNN